In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)

BACKGROUND: CABP is the number one reason for death by infectious diseases worldwide and emerging resistance complicates its treatment. Lefamulin is the first semi-synthetic pleuromutilin antibiotic for IV and oral use in humans. It is currently in Phase 3 trials for the treatment of CABP in adults....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Paukner, Susanne, Sader, Helio S, Streit, Jennifer M, Flamm, Robert K, Gelone, Steven P
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631057/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.916
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares